Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the Standard Comparator of Minimally Invasive Surgical Therapies (MIST) for Benign Prostatic Obstruction? Medical Versus Surgical Treatment.

European urology·2026
Same author

Urodynamics assessment in patients with multiple sclerosis.

BJUI compass·2026
Same author

Summary Paper on the 2026 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.

European urology·2026
Same author

Assessment of Perinatal Pelvic Floor Dysfunction Symptoms and Risk Factors: Measurement Properties of the International Consultation on Incontinence-Perinatal Pelvic Health Self-Assessment Questionnaire (ICIQ-PPHSAQ).

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Comparing the clinical and cost-effectiveness of various washout policies in preventing catheter associated complications in adults living with long-term catheters: synopsis of the CATHETER II RCT.

Health technology assessment (Winchester, England)·2026
Same author

The Evidence-based Role of Urodynamics in Men with Lower Urinary Tract Symptoms Considering Prostate Surgery: An International Expert Consensus.

European urology focus·2026
Same journal

Single Port Robotic Surgery in Benign Urologic Disease - A Review of Contemporary Applications and Outcomes.

Current urology reports·2026
Same journal

Effective Mentorship in Urology Fellowship Training: Qualities, Models, and Equity.

Current urology reports·2026
Same journal

Management of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis.

Current urology reports·2026
Same journal

Lower Urinary Tract Symptoms as an Indicator of Occult Neurologic Disease: A System-first Framework for Urologic Practice.

Current urology reports·2026
Same journal

Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis.

Current urology reports·2026
Same journal

Is Open Partial Nephrectomy Still an Option in the Robotic Era?

Current urology reports·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Emerging treatment options for benign prostatic obstruction.

Brian A Parsons1, Hashim Hashim

  • 1Bristol Urological Institute, Southmead Hospital, Bristol, UK.

Current Urology Reports
|April 9, 2011
PubMed
Summary
This summary is machine-generated.

Benign prostatic obstruction (BPO) impacts aging men, causing urinary issues and reduced quality of life. Emerging treatments offer new hope beyond current limited options.

More Related Videos

Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification
03:51

Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification

Published on: December 8, 2023

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jun 2, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification
03:51

Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification

Published on: December 8, 2023

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

  • Urology
  • Gerontology
  • Pharmacology

Background:

  • Benign prostatic obstruction (BPO) is a common condition in aging men.
  • BPO causes lower urinary tract symptoms, impacting quality of life and potentially leading to morbidity.
  • Existing treatments for BPO have limitations including adverse events and invasiveness.

Purpose of the Study:

  • To review emerging treatment options for benign prostatic obstruction.
  • To highlight novel pharmacological agents and minimally invasive interventions for BPO.

Main Methods:

  • Literature review of recent research on BPO pathogenesis.
  • Analysis of novel therapeutic interventions and pharmacological agents.

Main Results:

  • Research into BPO pathogenesis has advanced significantly.
  • Development of new pharmacological agents and minimally invasive treatments is ongoing.
  • Emerging options aim to overcome limitations of current BPO therapies.

Conclusions:

  • Novel treatments for BPO are being developed.
  • These emerging options may offer improved efficacy and safety profiles.
  • Further research is needed to establish the full potential of these new BPO treatments.